A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in Combination with Anti-PD-1 Antibody in Subjects with Advanced Solid Tumours.

  • Markman, Ben (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date26/04/22 → 31/12/24

Keywords

  • Medical oncology
  • Clinical trial

Clinical Trial Phase

  • Phase I
  • Phase II